LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

Home・Lista de Ações・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Abrir

SetorSaúde

509.12 1.06

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

503.81

Máximo

519.07

Indicadores-chave
By Trading Economics
Rendimento	-36M -94M
Vendas	-9.7M 311M
EPS	-1.38
Margem de lucro	-30.318
Funcionários	915
EBITDA	-43M -93M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+31.31% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	156M 12B
Abertura anterior	508.06
Fecho anterior	509.12

Sentimento de Notícias

By Acuity

50%

148 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

263.2 / 277.1 Suporte e Resistência

Madrigal Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

21 de mai. de 2026, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 de mai. de 2026, 16:49 UTC

Ganhos

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 de mai. de 2026, 16:26 UTC

Grandes Movimentos do Mercado

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

21 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 de mai. de 2026, 22:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Conduent to Sell Public Transit Business to Modaxo for $164M

21 de mai. de 2026, 21:53 UTC

Ganhos

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 de mai. de 2026, 21:02 UTC

Ganhos

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 de mai. de 2026, 20:55 UTC

Ganhos

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 de mai. de 2026, 20:30 UTC

Ações em Alta

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 de mai. de 2026, 20:20 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 de mai. de 2026, 20:20 UTC

Conversa de Mercado

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 de mai. de 2026, 20:20 UTC

Ganhos

Webull 1Q Adj EPS 3c >BULL

21 de mai. de 2026, 20:20 UTC

Ganhos

Webull 1Q Rev $159.9M >BULL

21 de mai. de 2026, 20:18 UTC

Conversa de Mercado

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 de mai. de 2026, 20:18 UTC

Ganhos

Webull 1Q Loss/Shr 4c

21 de mai. de 2026, 19:43 UTC

Conversa de Mercado

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 de mai. de 2026, 19:33 UTC

Conversa de Mercado

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 de mai. de 2026, 18:58 UTC

Ganhos

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 de mai. de 2026, 18:15 UTC

Conversa de Mercado

Gold Higher For Second Consecutive Day -- Market Talk

21 de mai. de 2026, 17:40 UTC

Conversa de Mercado

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 de mai. de 2026, 17:04 UTC

Conversa de Mercado

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 de mai. de 2026, 17:01 UTC

Ganhos

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Ganhos

Stellantis Targets Distant but Constructive -- Market Talk

21 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

Comparação entre Pares

Variação de preço

Madrigal Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

31.31% parte superior

Previsão para 12 meses

Média 674.25 USD 31.31%

Máximo 964 USD

Mínimo 550 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Madrigal Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Madrigal Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

263.2 / 277.1Suporte e Resistência

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimento

By Acuity

148 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.